Metoprolol (D) is the most likely culprit for worsening psoriasis in this post-MI patient.
Among the listed medications, beta-blockers like metoprolol are the most strongly implicated in triggering or exacerbating psoriasis, making it the primary suspect in this clinical scenario.
Evidence Supporting Beta-Blocker Association
The Joint AAD-NPF Guidelines 1 specifically address beta-blockers and psoriasis, citing a study demonstrating that long-term regular use of β-blockers for ≥6 years showed a statistically significant association with psoriasis development (OR 1.39,95% CI 1.11-1.73). While the guidelines note some conflicting data from a UK cohort showing no association, beta-blockers remain among the classic drug triggers for psoriasis alongside lithium, antimalarials, and NSAIDs 2.
Recent pharmacovigilance data 3 identified acebutolol (a beta-blocker) among 30 drugs showing significant associations with psoriasis in real-world analysis, further supporting the beta-blocker class effect.
Why Not the Other Options?
Aspirin (E): While NSAIDs are classically associated with psoriasis exacerbation 2, aspirin at cardioprotective doses (typically 81mg) is rarely implicated in clinical practice
Clopidogrel (A): No established association with psoriasis induction or exacerbation in the literature
Atorvastatin (B): Actually shows protective cardiovascular effects in psoriasis patients. The guidelines 1 demonstrate statins have a hazard ratio of 0.31 (95% CI 0.23-0.43, P<.001) for cardiovascular events, indicating benefit rather than harm
Omeprazole (C): Not recognized as a psoriasis trigger in major reviews or guidelines
Clinical Management Approach
The dilemma: This patient needs beta-blocker therapy post-MI for mortality benefit, but it's worsening their psoriasis.
Practical algorithm:
- Confirm the temporal relationship - Did psoriasis worsen within weeks to months of starting metoprolol?
- Assess severity - Is the psoriasis exacerbation mild (manageable with topicals) or severe (significantly impacting quality of life)?
- If mild-moderate: Continue metoprolol given its mortality benefit post-MI, optimize psoriasis treatment with topical corticosteroids or systemic therapy if needed
- If severe: Consider switching to alternative post-MI medications (ACE inhibitors, though note these can occasionally trigger psoriasis 4) while recognizing you're sacrificing some beta-blocker-specific benefit
Important Caveats
The guidelines 1 conclude that "the preponderance of the evidence does not support the avoidance of particular antihypertensive medications (β-blockers, calcium-channel blockers, or others) in patients with psoriasis" - meaning the cardiovascular benefit often outweighs the dermatologic risk. However, this statement addresses prevention in patients with existing psoriasis, not management of active exacerbation.
In this specific case where worsening has already occurred, metoprolol remains the most likely offender and warrants discussion with cardiology about risk-benefit of continuation versus alternative post-MI management strategies.